BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 25929957)

  • 21. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
    Li Y; Pan Y; Wang R; Sun Y; Hu H; Shen X; Lu Y; Shen L; Zhu X; Chen H
    PLoS One; 2013; 8(7):e69016. PubMed ID: 23922677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.
    Le Quesne J; Maurya M; Yancheva SG; O'Brien M; Popat S; Wotherspoon AC; de Castro DG; Nicholson AG
    J Thorac Oncol; 2014 Jun; 9(6):769-74. PubMed ID: 24787965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
    J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
    Marchetti A; Pace MV; Di Lorito A; Canarecci S; Felicioni L; D'Antuono T; Liberatore M; Filice G; Guetti L; Mucilli F; Buttitta F
    Lung Cancer; 2016 Sep; 99():11-6. PubMed ID: 27565907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
    J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.
    Ilie M; Long E; Butori C; Hofman V; Coelle C; Mauro V; Zahaf K; Marquette CH; Mouroux J; Paterlini-Bréchot P; Hofman P
    Ann Oncol; 2012 Nov; 23(11):2907-2913. PubMed ID: 22735679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
    Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
    Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.
    Just PA; Cazes A; Audebourg A; Cessot A; Pallier K; Danel C; Vacher-Lavenu MC; Laurent-Puig P; Terris B; Blons H
    Lung Cancer; 2012 Jun; 76(3):309-15. PubMed ID: 22153831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
    Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
    PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
    Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
    Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
    J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
    Trejo Bittar HE; Luvison A; Miller C; Dacic S
    Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.